TSX:DHT.UN - Post by User
Post by
retiredcfon Jun 30, 2023 9:25am
162 Views
Post# 35521992
RBC
RBCJune 29, 2023
Announces Orserdu royalty acquisition resulting in flat to slightly growing cash receipts to 2030E
TSX: DHT-U | CAD 10.38 | Outperform | Price Target CAD 17.00
Sentiment: Positive
Our initial view: We view the announced royalty transaction on Orserdu as positive for the shares, given it should address the declining cash royalty receipts between 2025E and 2030E, following the Tzield sale. After today's transaction, DRI management expects flat to slightly growing royalty cash receipts through 2030. Orserdu is marketed by Stemline Therapeutics, a subsidiary of the Menarini Group. Orserdu is the first and only approved targeted therapy used in the treatment of postmenopausal women or adult men with ESR1-mutated ER+/HER2- metastatic breast cancer, who have experienced disease progression despite prior endocrine therapy. Orserdu was approved by the FDA in January 2023 and is under review by the European Medicines Agency for potential approval. Following today's transaction DRI will have additional $200-250MM of liquidity to fund future acquisitions.
Transaction details: DRI purchased a royalty interest in the worldwide net sales of Orserdu from Eisai for $85MM. The acquisition entitles DRI Healthcare to a mid-single-digit tiered royalty on the worldwide net sales of the Orserdu. DRI will receive quarterly royalty payments on a one-quarter lag based on sales beginning 01-Apr-23, with its first payment expected to be received in Q3 2023. DRI is also entitled to receive milestones based on the achievement of regulatory and sales performance thresholds. Management expects this transaction to result in flat to slightly growing royalty cash receipts through 2030. We note that with the original Tzield royalty acquisition, the company had addressed the declining cash royalties between 2025E and 2030E. However, after selling the Tzield royalty to Sanofi at an attractive 2.1x cash return (here), the cash receipts were expected to decline between 2025E-2030E. DRI has now addressed this decline with the announced royalty transaction today.
Details on Orserdu (elacestrant): Orserdu is an oral selective estrogen receptor degrader (SERD) specifically designed for postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy. Orserdu provides statistically significant benefit in terms of median progression- free survival (mPFS) when compared to standard-of-care treatments. Patients who have been treated with CDK4/6 inhibitors for at least 12 months experienced a mPFS of 8.6 months compared to 1.9 months with standard-of-care therapies. Orserdu is administered orally once daily unlike other traditional SERDs that are administered intramuscularly and as such, provides patients with a more convenient and less painful treatment option. Orserdu has a discontinuation rate of less than 4%. The drug is patent protected up to January 2038 with six patents listed in the FDA's Orange Book.